| |
OS
|
RFS
|
|---|
|
Univariate analysis
|
Multivariate analysisa
|
Univariate analysis
|
Multivariate analysisa
|
|---|
|
Variables
|
HR
|
95 % CI
|
p
|
HR
|
95 % CI
|
p
|
HR
|
95 % CI
|
p
|
HR
|
95 % CI
|
p
|
|---|
|
Age
|
1.50
|
1.01–2.89
|
0.092
| | | |
1.12
|
0.62–2.36
|
0.147
| | | |
|
(≤65 vs. > 65)
|
|
Sex
|
1.09
|
0.61–1.79
|
0.671
| | | |
0.86
|
0.43–1.58
|
0.704
| | | |
|
(female vs. male)
|
|
Tobacco use
|
1.26
|
1.17–3.08
|
0.143
| | | |
1.03
|
0.52–1.97
|
0.766
| | | |
|
(no vs. yes)
|
|
TNM stage
|
3.25
|
1.66–5.91
|
0.0007
|
2.02
|
0.93–4.37
|
0.012
|
3.08
|
1.49–6.24
|
0.0009
|
2.27
|
1.09–5.45
|
0.010
|
|
(I vs. II–III)
|
|
pT status
|
1.65
|
0.88–2.89
|
0.070
| | | |
1.22
|
0.57–2.39
|
0.198
| | | |
|
(T1 vs. T2-4)
|
|
pN status
|
4.19
|
2.10–7.72
|
0.0005
|
2.34
|
1.02–5.99
|
0.005
|
3.55
|
1.71–7.23
|
0.0004
|
2.76
|
1.46–5.89
|
0.003
|
|
(N0 vs. N1-2)
|
|
Pleural involvement
|
0.77
|
0.31–1.52
|
0.830
| | | |
0.67
|
0.39–1.43
|
0.902
| | | |
|
(no vs. yes)
|
|
Differentiation (well/moderate vs. poor)
|
1.32
|
0.72–2.61
|
0.127
| | | |
1.07
|
0.51–1.91
|
0.722
| | | |
|
Foxc2 expression
|
1.98
|
0.75–3.92
|
0.036
|
1.90
|
0.76–4.05
|
0.039
|
2.13
|
1.08–4.15
|
0.011
|
1.54
|
0.89–3.67
|
0.077
|
|
(low vs. high)
|
|
E-cadherin expression
|
2.03
|
0.97–4.12
|
0.024
|
1.77
|
0.79–3.78
|
0.098
|
2.09
|
1.12–4.37
|
0.043
|
1.38
|
0.65–2.99
|
0.092
|
|
(preserved vs. impaired)
| | | | | | | | | | | | |
|
Foxc2/E-cadherin expression
|
|
1 vs. 2
|
1.45
|
0.63–2.80
|
0.117
| | | |
1.35
|
0.76–2.55
|
0.122
| | | |
|
1 vs. 3
|
1.70
|
0.88–3.23
|
0.062
| | | |
1.47
|
0.71–2.68
|
0.103
| | | |
|
1 vs. 4
|
3.04
|
1.23–5.75
|
0.0009
|
2.41
|
1.12–4.67
|
0.002
|
2.55
|
1.29–5.16
|
0.008
|
2.06
|
0.87–4.17
|
0.035
|
|
1 vs. 2 + 3 + 4
|
1.85
|
0.90–3.53
|
0.026
|
1.34
|
0.64–2.23
|
0.168
|
1.56
|
0.74–3.05
|
0.071
| | | |
-
OS overall survival; RFS recurrence-free survival
-
aVariables were adopted for their prognostic significance by univariate analysis
